Evidence map›Paper›PMID 25990290›Full record

SynthesisAnnals of the rheumatic diseases2016

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update.

Michaela A Stoffer, Monika M Schoels, Josef S Smolen, Daniel Aletaha, Ferdinand C Breedveld, Gerd Burmester, Vivian Bykerk, Maxime Dougados, Paul Emery, Boulos Haraoui and 8 more

Erratum issuedAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of the rheumatic diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 123 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

123 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Guideline
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Th17 and CD24Arthritis research & therapy · 2017
    Trial
  15. Trial
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Michaela A StofferDivision of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria University of Applied Sciences for Health Professions Upper Austria, Linz, Austria.
Monika M SchoelsDepartment of Internal Medicine, Centre for Rheumatic Diseases, Hietzing Hospital, Vienna, Austria.
Josef S SmolenDivision of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria Department of Internal Medicine, Centre for Rheumatic Diseases, Hietzing Hospital, Vienna, Austria.
Daniel AletahaDivision of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.
Ferdinand C BreedveldDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Gerd BurmesterDepartment of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany.
Vivian BykerkDivision of Rheumatology, Weill Cornell Medical College, Cornell University, Hospital for Special Surgery, New York, USA.
Maxime DougadosDepartment of Rheumatology, Hôpital Cochin, Paris Descartes University, Assistance Publique-Hôpitaux de Paris; INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France.
Paul EmeryAcademic Unit of Musculoskeletal Disease, University of Leeds, Leeds, UK.
Boulos HaraouiRheumatic Disease Unit, University of Montreal, Montreal, Canada.
Juan Gomez-ReinoRheumatology Service and Department of Medicine, Hospital Clinico Universitario, Universidad de Santiago, Spain.
Tore K KvienDepartment of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
Peter NashDepartment of Medicine, University of Queensland, Brisbane, Australia.
Victoria Navarro-CompánDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands Department of Rheumatology, University Hospital La Paz, Madrid, Spain.
Marieke Scholte-VoshaarDepartment of Psychology, Health and Technology, University of Twente, Enschede, The Netherlands.
Ronald van VollenhovenThe Karolinska Institute, Stockholm, Sweden.
Désirée van der HeijdeDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0002-5781-158X
Tanja A StammDivision of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.

Funding

Versus Arthritis 18475
6 · The paper itself

Abstract

objectiveA systematic literature review (SLR; 2009-2014) to compare a target-oriented approach with routine management in the treatment of rheumatoid arthritis (RA) to allow an update of the treat-to-target recommendations.

methodsTwo SLRs focused on clinical trials employing a treatment approach targeting a specific clinical outcome were performed. In addition to testing clinical, functional and/or structural changes as endpoints, comorbidities, cardiovascular risk, work productivity and education as well as patient self-assessment were investigated. The searches covered MEDLINE, EMBASE, Cochrane databases and Clinicaltrial.gov for the period between 2009 and 2012 and separately for the period of 2012 to May of 2014.

resultsOf 8442 citations retrieved in the two SLRs, 176 articles underwent full-text review. According to predefined inclusion/exclusion criteria, six articles were included of which five showed superiority of a targeted treatment approach aiming at least at low-disease activity versus routine care; in addition, publications providing supportive evidence were also incorporated that aside from expanding the evidence provided by the above six publications allowed concluding that a target-oriented approach leads to less comorbidities and cardiovascular risk and better work productivity than conventional care.

conclusionsThe current study expands the evidence that targeting low-disease activity or remission in the management of RA conveys better outcomes than routine care.

Indexed as

Patient Care PlanningSeverity of Illness IndexAntirheumatic AgentsArthritis, RheumatoidClinical Trials as TopicComorbidityEvidence-Based MedicineHumansRadiographyTreatment OutcomeAntirheumatic AgentsDisease ActivityRheumatoid ArthritisTreatment

Identifiers

PMID25990290
PMCPMC4717391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.